Myovant Sciences to Present at Upcoming December Investor Conferences
Myovant Sciences (NYSE: MYOV) has announced participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Myovant Sciences (NYSE: MYOV) has announced participation in two upcoming investor conferences. On December 1, 2020, executives will present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference at 4:45 p.m. Eastern time, followed by virtual one-on-one meetings. Also, Dr. Lynn Seely will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference with a pre-recorded presentation available at 10 a.m. Eastern time. These presentations can be accessed on Myovant's Investors & Media website section.
Details
News Market Reaction – MYOV
The recorded move for MYOV in the trading session of this news was +5.19%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BASEL, Switzerland, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences:
- Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 1, 2020 at 4:45 p.m. Eastern time. Lynn Seely, M.D., chief executive officer of Myovant Sciences, Inc., and Frank Karbe, president and chief financial officer of Myovant Sciences, Inc., will participate in a webcast presentation. Management will also participate in virtual one-on-one investor meetings on December 1.
- Piper Sandler 32nd Annual Virtual Healthcare Conference. A pre-recorded presentation by Dr. Seely will be available at 10 a.m. Eastern time today on the investor relations page of Myovant’s website, investors.myovant.com. Management will participate in virtual one-on-one investor meetings on December 3, 2020.
The presentations will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com.
About Myovant Sciences
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our lead product candidate, relugolix, is a once-daily, oral GnRH receptor antagonist. Relugolix monotherapy tablet (120 mg) is under regulatory review in the U.S. for men with advanced prostate cancer. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.
Investor Contact:
Ryan Crowe
Vice President, Investor Relations
Myovant Sciences, Inc.
investors@myovant.com
Media Contact:
Albert Liao
Director, Corporate Communications
Myovant Sciences, Inc.
media@myovant.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.